Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 25217 results found since Jan 2013.
The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy
CONCLUSION: Favorable bRFS after SRT in patients with BR and negative PSMA-PET following RP was achieved. These data support the usage of early SRT for patients with negative PSMA-PET findings.PMID:37736808 | DOI:10.1007/s00259-023-06438-3
Source: Molecular Medicine - September 22, 2023 Category: Molecular Biology Authors: Sonja Adebahr Alexander Althaus Sophia Scharl Iosif Strouthos Andrea Farolfi Francesca Serani Helena Lanzafame Christian Trapp Stefan A Koerber Jan C Peeken Marco M E Vogel Alexis Vrachimis Simon K B Spohn Anca-Ligia Grosu Stephanie G C Kroeze Matthias Gu Source Type: research
Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft model
In conclusion, we found that specific targeting might negatively influence normal organ uptake when targeting secreted antigens. Furthermore, different energy deposition i.e. linear energy transfer of a radionuclide might have diverse effects on receptor expression and cell proliferation in tumors.PMID:37736493 | PMC:PMC10509292
Source: Molecular Medicine - September 22, 2023 Category: Molecular Biology Authors: Oskar Vilhelmsson Timmermand Marcella Safi Bo Holmqvist Joanna Strand Source Type: research
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
CONCLUSION: The trial reached its primary end point of biochemical control and PFS, suggesting a clinical advantage for SBRT in addition to first-line AAP treatment in patients with metastatic castration-resistant prostate cancer.PMID:37733977 | DOI:10.1200/JCO.23.00985
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Giulio Francolini Andrea Gaetano Allegra Beatrice Detti Vanessa Di Cataldo Saverio Caini Alessio Bruni Gianluca Ingrosso Rolando Maria D'Angelillo Anna Rita Alitto Matteo Augugliaro Luca Triggiani Silvana Parisi Gaetano Facchini Marco Banini Gabriele Simo Source Type: research
Aggressive variant prostate cancer: A case report and literature review
CONCLUSION: We should reach consensus definitions of the AVPC and other androgen receptor-independent subtypes of PCA and develop new biomarkers to identify groups of high-risk variants. It is crucial to complete a puncture biopsy of the tumor or metastatic lesion as soon as possible in patients with advanced PCA who exhibit clinical features such as low Prostate-specific antigen levels, high carcinoembryonic antigen levels, and insensitivity to hormones to determine the pathological histological type and to create a more aggressive monitoring and treatment regimens.PMID:37731555 | PMC:PMC10507546 | DOI:10.12998/wjcc.v11.i26.6213
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xiang-Tao Weng Wen-Li Lin Qi-Man Pan Tao-Fen Chen Si-Yi Li Chi-Ming Gu Source Type: research
The active phthalate metabolite, DHEP, induces proliferation and metastasis of prostate cancer cells via upregulation of β-catenin and downregulation of KLF7
Bioorg Chem. 2023 Sep 15;141:106864. doi: 10.1016/j.bioorg.2023.106864. Online ahead of print.ABSTRACTPhthalates such as DHEP are among the widely used compounds in industry. It has been shown that DHEP can convey various biological consequences in mammalian cells, among them, the carcinogenic effects of DHEP are emphasized. The present study aimed to assess the impact of DHEP exposure on the proliferation and invasiveness of DU145 prostate cancer cells through in vitro and in vivo models. The DU145 cells were treated with increasing concentrations of DHEP and the tumorigenic parameters were analyzed. KLF7 as a probable me...
Source: Bioorganic Chemistry - September 21, 2023 Category: Chemistry Authors: Hecheng Li Jianping Li Yubo Ma Ziming Wang Zihe Peng Hang Xu Hang Bi Shaik Althaf Hussain Zhaolun Li Source Type: research
Development and evaluation of the MiCheck ® Prostate test for clinically significant prostate cancer
CONCLUSIONS: The MiCheck® Prostate test identifies clinically significant prostate cancer with high sensitivity and negative predictive value (NPV). It can be performed in a clinical laboratory using a Roche Cobas clinical chemistry analyzer. The MiCheck® Prostate test could assist in reducing unnecessary prostate biopsies with a marginal number of patients experiencing a delayed diagnosis.PMID:37734979 | DOI:10.1016/j.urolonc.2023.08.005
Source: Ann Oncol - September 21, 2023 Category: Cancer & Oncology Authors: Neal D Shore Dmitry M Polikarpov Christopher M Pieczonka R Jonathan Henderson James L Bailen Daniel R Saltzstein Raoul S Concepcion Jennifer L Beebe-Dimmer Julie J Ruterbusch Rachel A Levin Sandra Wissmueller Thao Ho Le David A Gillatt Daniel W Chan Niant Source Type: research
Emerging proteins involved in castration ‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review)
Int J Oncol. 2023 Nov;63(5):127. doi: 10.3892/ijo.2023.5575. Epub 2023 Sep 21.ABSTRACTDespite achieving optimal initial responses to androgen deprivation therapy, most patients with prostate cancer eventually progress to a poor prognosis state known as castration‑resistant prostate cancer (CRPC). Currently, there is a notable absence of reliable early warning biomarkers and effective treatment strategies for these patients. Although androgen receptor (AR)‑independent pathways have been discovered and acknowledged in recent years, the AR signaling pathway continues to play a pivotal role in the progression of CRPC. The ...
Source: International Journal of Oncology - September 21, 2023 Category: Cancer & Oncology Authors: Kangle Feng Chunhua Liu Weixi Wang Piaoping Kong Zhihua Tao Weiwei Liu Source Type: research
Development and evaluation of the MiCheck ® Prostate test for clinically significant prostate cancer
CONCLUSIONS: The MiCheck® Prostate test identifies clinically significant prostate cancer with high sensitivity and negative predictive value (NPV). It can be performed in a clinical laboratory using a Roche Cobas clinical chemistry analyzer. The MiCheck® Prostate test could assist in reducing unnecessary prostate biopsies with a marginal number of patients experiencing a delayed diagnosis.PMID:37734979 | DOI:10.1016/j.urolonc.2023.08.005
Source: Urologic Oncology - September 21, 2023 Category: Urology & Nephrology Authors: Neal D Shore Dmitry M Polikarpov Christopher M Pieczonka R Jonathan Henderson James L Bailen Daniel R Saltzstein Raoul S Concepcion Jennifer L Beebe-Dimmer Julie J Ruterbusch Rachel A Levin Sandra Wissmueller Thao Ho Le David A Gillatt Daniel W Chan Niant Source Type: research
Aggressive variant prostate cancer: A case report and literature review
CONCLUSION: We should reach consensus definitions of the AVPC and other androgen receptor-independent subtypes of PCA and develop new biomarkers to identify groups of high-risk variants. It is crucial to complete a puncture biopsy of the tumor or metastatic lesion as soon as possible in patients with advanced PCA who exhibit clinical features such as low Prostate-specific antigen levels, high carcinoembryonic antigen levels, and insensitivity to hormones to determine the pathological histological type and to create a more aggressive monitoring and treatment regimens.PMID:37731555 | PMC:PMC10507546 | DOI:10.12998/wjcc.v11.i26.6213
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xiang-Tao Weng Wen-Li Lin Qi-Man Pan Tao-Fen Chen Si-Yi Li Chi-Ming Gu Source Type: research
Emerging proteins involved in castration ‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review)
Int J Oncol. 2023 Nov;63(5):127. doi: 10.3892/ijo.2023.5575. Epub 2023 Sep 21.ABSTRACTDespite achieving optimal initial responses to androgen deprivation therapy, most patients with prostate cancer eventually progress to a poor prognosis state known as castration‑resistant prostate cancer (CRPC). Currently, there is a notable absence of reliable early warning biomarkers and effective treatment strategies for these patients. Although androgen receptor (AR)‑independent pathways have been discovered and acknowledged in recent years, the AR signaling pathway continues to play a pivotal role in the progression of CRPC. The ...
Source: International Journal of Oncology - September 21, 2023 Category: Cancer & Oncology Authors: Kangle Feng Chunhua Liu Weixi Wang Piaoping Kong Zhihua Tao Weiwei Liu Source Type: research
Practical Guidance on 177LuLu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling
Clin J Oncol Nurs. 2023 Sep 15;27(5):539-547. doi: 10.1188/23.CJON.539-547.ABSTRACTBACKGROUND: The approval of the prostate-specific membrane antigen (PSMA)-targeted radio-ligand therapy [177Lu]Lu-PSMA-617 represents a shift toward precision medicine-based treatments for metastatic castration-resistant prostate cancer.OBJECTIVES: This review aims to provide practical advice and clinical considerations for working with [177Lu]Lu-PSMA-617; particularly, regarding the role of nurses in managing radiation safety, monitoring and reporting of adverse events, and counseling patients receiving this therapy.METHODS: Clinical data, ...
Source: Clinical Journal of Oncology Nursing - September 20, 2023 Category: Nursing Authors: Avery Spitz Rebecca Floyd Jennifer Sutton Linda Gardner Source Type: research
Comparison of Health-Related Quality of Life Changes in Prostate Cancer Patients Undergoing Laparoscopic versus Robotic-Assisted Laparoscopic Radical Prostatectomy: A Systematic review
CONCLUSION: Both robotic-assisted and laparoscopic radical prostatectomy are valid treatment options to achieve a good quality of life following surgery. The intermediate and long-term results in regard to QoL are comparable between the two procedures. RALRP might be superior to LRP in terms of immediate health-related quality of life, which might contribute to early recovery of urinary function.PMID:37727913 | DOI:10.22037/uj.v20i.7707
Source: Urology Journal - September 20, 2023 Category: Urology & Nephrology Authors: Sertac Yazici Senol Tonyali Source Type: research
Practical Guidance on 177LuLu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling
Clin J Oncol Nurs. 2023 Sep 15;27(5):539-547. doi: 10.1188/23.CJON.539-547.ABSTRACTBACKGROUND: The approval of the prostate-specific membrane antigen (PSMA)-targeted radio-ligand therapy [177Lu]Lu-PSMA-617 represents a shift toward precision medicine-based treatments for metastatic castration-resistant prostate cancer.OBJECTIVES: This review aims to provide practical advice and clinical considerations for working with [177Lu]Lu-PSMA-617; particularly, regarding the role of nurses in managing radiation safety, monitoring and reporting of adverse events, and counseling patients receiving this therapy.METHODS: Clinical data, ...
Source: Clinical Prostate Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Avery Spitz Rebecca Floyd Jennifer Sutton Linda Gardner Source Type: research
Comparison of Health-Related Quality of Life Changes in Prostate Cancer Patients Undergoing Laparoscopic versus Robotic-Assisted Laparoscopic Radical Prostatectomy: A Systematic review
CONCLUSION: Both robotic-assisted and laparoscopic radical prostatectomy are valid treatment options to achieve a good quality of life following surgery. The intermediate and long-term results in regard to QoL are comparable between the two procedures. RALRP might be superior to LRP in terms of immediate health-related quality of life, which might contribute to early recovery of urinary function.PMID:37727913 | DOI:10.22037/uj.v20i.7707
Source: Urology Journal - September 20, 2023 Category: Urology & Nephrology Authors: Sertac Yazici Senol Tonyali Source Type: research
